A detailed history of Altman Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Altman Advisors, Inc. holds 20,875 shares of GILD stock, worth $1.87 Million. This represents 0.78% of its overall portfolio holdings.

Number of Shares
20,875
Previous 20,622 1.23%
Holding current value
$1.87 Million
Previous $1.41 Million 23.69%
% of portfolio
0.78%
Previous 0.81%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$66.59 - $83.99 $16,847 - $21,249
253 Added 1.23%
20,875 $1.75 Million
Q2 2024

Aug 07, 2024

BUY
$63.15 - $72.88 $34,985 - $40,375
554 Added 2.76%
20,622 $1.41 Million
Q1 2024

May 08, 2024

BUY
$71.58 - $87.29 $62,775 - $76,553
877 Added 4.57%
20,068 $1.47 Million
Q4 2023

Feb 07, 2024

SELL
$73.27 - $83.09 $9,671 - $10,967
-132 Reduced 0.68%
19,191 $1.55 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $13,161 - $14,359
178 Added 0.93%
19,323 $1.45 Million
Q1 2023

May 09, 2023

BUY
$77.31 - $88.08 $28,140 - $32,061
364 Added 1.94%
19,145 $1.59 Million
Q4 2022

Feb 08, 2023

SELL
$62.32 - $89.47 $41,006 - $58,871
-658 Reduced 3.38%
18,781 $1.61 Million
Q3 2022

Nov 07, 2022

BUY
$59.54 - $68.01 $1.16 Million - $1.32 Million
19,439 New
19,439 $1.2 Million
Q4 2020

Feb 10, 2021

SELL
$56.65 - $64.55 $342,959 - $390,785
-6,054 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$62.1 - $78.08 $1.54 Million - $1.93 Million
-24,723 Reduced 80.33%
6,054 $383,000
Q2 2020

Aug 12, 2020

SELL
$72.34 - $84.0 $5,425 - $6,300
-75 Reduced 0.24%
30,777 $2.37 Million
Q1 2020

Apr 20, 2020

BUY
$62.63 - $80.22 $1.93 Million - $2.47 Million
30,852 New
30,852 $2.31 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Altman Advisors, Inc. Portfolio

Follow Altman Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altman Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Altman Advisors, Inc. with notifications on news.